The Shift to High Concentration mAbs: 3 Critical UF/DF Challenges and How to Solve Them
As monoclonal antibody therapies continue to evolve, the industry is rapidly shifting from traditional mAb formulations to high concentration mAbs to enable subcutaneous delivery, improve patient convenience, and support next generation therapeutics. While this shift delivers clear clinical benefits, it also introduces new risks and complexities particularly during ultrafiltration and diafiltration (UF/DF).
In this webinar, we’ll examine how increasing protein concentration fundamentally changes UF/DF behavior—and why legacy approaches often struggle as viscosity rises and operating windows narrow. We’ll break down the three most critical UF/DF challenges associated with high concentration mAbs and discuss practical strategies to address them using modern TFF platforms.
Key topics include:
- Why the industry is shifting toward high concentration mAbs—and what this means for downstream bioprocessing
- The three critical UF/DF challenges at high concentration:
- Managing viscosity and its impact on flux, pressure, and process control
- Preventing fouling and polarization that limit performance and scalability
- Reducing aggregation risk during concentration and diafiltration
- How modern, automated TFF system design can help mitigate these risks
- What to consider when adapting UF/DF strategies for development, scale up, and manufacturing
Whether you are developing next generation mAbs or scaling existing programs to higher concentrations, this session will provide practical insights to help you build more robust, repeatable UF/DF processes for the high concentration era.
May 04, 2026
Discover More Webinars
Webinar
Strategies for dsRNA Removal and Accurate Quantitation in Emerging mRNA Modalities
May 12
Webinar
The Shift to High Concentration mAbs: 3 Critical UF/DF Challenges and How to Solve Them
May 4
Webinar
How Small-Scale Chromatography Models Transform mAb Viral Clearance and Process Characterization
Feb 19
Webinar
Four Common Pitfalls to Avoid in UF/DF Setup and Scale-Up
Feb 19
Webinar
Antibody–Drug Conjugate Manufacturing: Driving Process Productivity and Reducing Risk
Oct 30
